{"id":61542,"date":"2025-07-08T07:06:53","date_gmt":"2025-07-08T05:06:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/"},"modified":"2025-07-08T07:06:53","modified_gmt":"2025-07-08T05:06:53","slug":"invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/","title":{"rendered":"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–#invivoscribe<\/a>–Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThrough this collaboration, LabPMM (Invivoscribe\u2019s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support <\/b>CERo\u2019s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed\/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS\/AML.<\/p>\n

\nAML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 <\/sup>Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells (\u201cCER-T\u201d) therapies, which involve engineering a patient\u2019s own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it’s critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product \u2013 underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM.<\/p>\n

\nLabPMM\u2019s CAP\/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo\u2019s drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial.<\/p>\n

\nKristen Pierce, Ph.D., CERo Chief Development Officer, commented, \u201cInvivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response.\u201d<\/p>\n

\nThis collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML2<\/sup>. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe\u2019s commitment to driving innovation and standardization across the oncology treatment landscape \u2013 now helping bring immunotherapies to patients faster.<\/p>\n

\nFor more information about LabPMM\u2019s flow cytometry and molecular testing services, please visit https:\/\/invivoscribe.com\/clinical-lab-services\/<\/a> or contact us at inquiry@invivoscribe.com<\/a> and follow us on LinkedIn.<\/p>\n

\nAbout Invivoscribe Inc.<\/b><\/p>\n

\nInvivoscribe\u00ae<\/sup> is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics\u00ae<\/sup>. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM\u00ae<\/sup>), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.<\/p>\n

\nAbout CERo Therapeutics Holdings, Inc.<\/b><\/p>\n

\nCERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body\u2019s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (\u201cCER-T\u201d). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (\u201cCAR-T\u201d) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.<\/p>\n

\n1<\/sup> https:\/\/www.cancer.net\/cancer-types\/leukemia-acute-myeloid-aml\/introduction<\/a>
2 <\/sup>https:\/\/www.cero.bio\/press-release?storyId=7477275225065985<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\ninquiry@invivoscribe.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–#invivoscribe–Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe\u2019s global reference laboratories) have customized their multiparametric … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61542","6":"format-standard","7":"category-industry"},"yoast_head":"\nInvivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–#invivoscribe–Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe\u2019s global reference laboratories) have customized their multiparametric ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-08T05:06:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250707133010\/en\/818522\/22\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial\",\"datePublished\":\"2025-07-08T05:06:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/\"},\"wordCount\":765,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250707133010\\\/en\\\/818522\\\/22\\\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/\",\"name\":\"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250707133010\\\/en\\\/818522\\\/22\\\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg\",\"datePublished\":\"2025-07-08T05:06:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250707133010\\\/en\\\/818522\\\/22\\\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250707133010\\\/en\\\/818522\\\/22\\\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–#invivoscribe–Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe\u2019s global reference laboratories) have customized their multiparametric ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/","og_site_name":"Pharma Trend","article_published_time":"2025-07-08T05:06:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250707133010\/en\/818522\/22\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial","datePublished":"2025-07-08T05:06:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/"},"wordCount":765,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250707133010\/en\/818522\/22\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/","url":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/","name":"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250707133010\/en\/818522\/22\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg","datePublished":"2025-07-08T05:06:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250707133010\/en\/818522\/22\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250707133010\/en\/818522\/22\/Invivoscribe-Logo-with-Tagline-Light-Version-New-RGB-101018-01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61542"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61542\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}